m+Medelevator.RU
← Поиск публикаций
Bioorganic chemistry · 2026

Diterpenoids from the leaves of Thuja orientalis L. and their inhibitory effects on PTP1B and α-glucosidase.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Vu Thi Oanh, Dinh Thi Nguyet Anh, Pham Thi Ly, Jung Yun-A, Byun Jun-Kyu, Min Byung Sun, Kim Jeong Ah

Аннотация

A phytochemical investigation of the leaves of Thuja orientalis L. resulted in the isolation and identification of 29 diterpenoids, including labdane, pimarane, and abietane derivatives. Among these, the new diterpenoid thujaorienin A (20) were characterized and eight labdane-type diterpenoids (15-16, 21-25 and 28) were reported for the first time from this species. This study provides a comprehensive diterpenoid profile of T. orientalis leaves. All isolated compounds were evaluated for protein tyrosine phosphatase 1B (PTP1B) and α-glucosidase inhibitory activities. Compounds 11 and 28 exhibited the most potent PTP1B inhibitory activity, with IC50 values of 12.3 ± 0.2 and 12.6 ± 1.0 μM, respectively. In addition, compounds 11 and 28 showed significant α-glucosidase inhibitory activity, with IC50 values of 9.2 ± 0.3 μM and 34.5 ± 5.5 μM, respectively. Enzyme kinetic analyses elucidated their inhibition mechanisms, and molecular docking studies supported the observed enzyme-ligand interactions. In cell-based assays, compound 11 exhibited no significant cytotoxicity and effectively inhibited intracellular PTP1B activity, resulting in enhanced phosphorylation of insulin receptor β (IRβ), insulin receptor substrate 1 (IRS1), and protein kinase B (AKT), as well as increased glucose uptake. These findings suggest that compound 11 from T. orientalis may serve as candidates for further investigation for their potential antidiabetic effects through PTP1B inhibition.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты